Incremental cost effectiveness of pharmacist-managed erythropoiesis- stimulating agent clinics for non-dialysis-dependent chronic kidney disease patients

Applied Health Economics and Health Policy

Volumn 11, Issue 6, 2013, Pages 653-660

  Aspinall, Sherrie L ^a,b,c   Smith, Kenneth J ^c   Good, Chester B ^a,b,c,f   Zhao, Xinhua ^b   Stone, Roslyn A ^b,d   Tonnu Mihara, Ivy Q ^e   Cunningham, Francesca E ^a  

^a VA Center for Medication Safety   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^e VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANALYSIS; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEALTH STATUS; HEMODIALYSIS; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MODEL; OUTPATIENT CARE; PARAMETERS; PATIENT CARE; PHARMACIST; PRACTICE GUIDELINE; PROBABILITY; PROSPECTIVE PAYMENT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; VETERANS HEALTH; WILLINGNESS TO PAY;

AGED; AMBULATORY CARE FACILITIES; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HEMATINICS; HOSPITALS, VETERANS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MARKOV CHAINS; PHARMACISTS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 84890509386     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-013-0057-6     Document Type: Article

References (21)

1. Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, Stone RA. Good CB for the ESA Clinic Study Group: impact of pharmacist-managed erythropoiesis-stimulating agents clinics for non-dialysis chronic kidney disease patients. Am J Kidney Dis. 2012;60:371-9.
2. Clapp SE, Bardo JA, Chrymko MM. Implementation of a pharmacist-managed clinic for patients receiving erythropoietin-stimulating agents. Am J Health Syst Pharm. 2008;65(15):1458-63.
3. Gilreath JA, Sageser DS, Jorgenson JA, Rodgers GM. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. JNCCN. 2008;6(6):577-84.
4. Kimura T, Arai M, Masuda H, Kawabata A. Impact of a pharmacist- implemented anemia management in outpatients with end-stage renal disease in Japan. Biol Pharm Bull. 2004;27(11):1831-3.
5. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
6. U.S. Department of Labor, Bureau of Labor Statistics, Consumer Price Index History Table. http://www.bls.gov/cpi/tables.htm. Accessed 1 August 2013.
7. National Kidney Foundation KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2006. http://www.kidney.org/professionals/KDOQI/guidelines-anemia/cpr31.htm and http://www.kidney.org/professionals/KDOQI/guidelines-anemia/cpr32.htm. Accessed 15 June 2011.
8. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
9. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32.
10. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-84.
11. Healthcare Cost and Utilization Project (HCUP). http://www.hcup-us.ahrq. gov. Accessed 19 December 2012.
12. Gorodetskaya I, Zenios S, McCullough CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801-8.
13. Tsevat J, Goldman L, Soukup JR, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Mak. 1993;13:161-5.
14. Havranek EP, McGovern KM, Weingerger J, et al. Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. J Card Fail. 1999;5:85-91.
15. Bosworth HB, Horner RD, Edwards LJ, et al. Depression and other determinants of values placed on current health state by stroke patients: evidence from the VA Acute Stroke Study. Stroke. 2000;31:2603-9.
16. Mittmann N, Trakas K, Risebrough N, Liu B. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15:369-76.
17. Bucaloiu ID, Akers G, Bernudez MC, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20(6):26-30.
18. FDA Press Announcements. FDA modifies dosing recommendations for erythropoiesis-stimulating agents, June 24, 2011. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm260670.htm. Accessed 18 December 2012.
19. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010;19(5):420-4.
20. Farag YM, Keithi-Reddy SR, Mittal BV, et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients. Clin Nephrol. 2011;75(6):524-33.
21. Joy MS, Candiani C, Vaillancourt BA, Chin H, Hogan SL, Falk RJ. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Pharmacotherapy. 2007;27(5):734-44.